GlassScriptPhysician profile
Ivan A Rivera Nazario
NPI 1124554449
$7,232.46
in general payments reported to CMS, 2019-2025
26 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $233 · 2021: $466 · 2022: $1,489 · 2023: $2,275 · 2024: $917 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,180 · Travel and Lodging: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,180.03 |
| Travel and Lodging | $626.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,130.50 | 2020-2025 | Jardiance |
| Medtronic, INC. | $923.78 | 2022-2025 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $581.03 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Eli Lilly Export S.A. Puerto Rico Branch | $453.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $407.67 | 2020-2023 | |
| Dexcom, INC. | $406.11 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $391.49 | 2019-2024 | Lokelma |
| Lilly USA, LLC | $343.68 | 2022-2025 | Zepbound, Jardiance |
| Amgen INC. | $332.47 | 2023-2024 | Repatha, Prolia |
| Abbott Laboratories | $322.34 | 2022-2025 | Freestyle Libre 3 |
| Pbg Puerto Rico LLC | $297.39 | 2021-2025 | |
| Horizon Therapeutics Plc | $235.41 | 2022-2023 | Tepezza |
| Abbvie INC. | $229.83 | 2023-2024 | Synthroid |
| Merck Sharp & Dohme LLC | $219.33 | 2019-2023 | Janumet, Steglatro, Januvia |
| Bayer Puerto Rico INC. | $218.83 | 2023-2025 | Kerendia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $211.62 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $126.55 | 2019-2022 | |
| Corcept Therapeutics | $104.19 | 2021-2024 | Korlym |
| Chiesi USA, INC. | $66.78 | 2021 | |
| Radius Health, INC. | $61.54 | 2022-2023 | Tymlos |
| Rhythm Pharmaceuticals, INC. | $45.58 | 2023 | Imcivree |
| Bayer Healthcare Pharmaceuticals INC. | $32.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $29.27 | 2020 | |
| Glaxosmithkline, LLC. | $24.43 | 2022 | |
| Pfizer INC. | $18.73 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Rivera Nazario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.